Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review.
Angela Ayén-RodríguezJosé Juan Pereyra-RodriguezFrancisco Jose Navarro-TriviñoSara Alcantara-LunaJavier Domínguez-CruzManuel Galán-GutiérrezSamuel Vilar-PalomoJose Carlos Armario-HitaRicardo Ruiz VillaverdePublished in: Life (Basel, Switzerland) (2022)
Today, different therapeutic options for AD patients can be prescribed. Individualizing the treatment allows for better therapeutic consistency, in addition to being cost-efficient to avoid primary therapeutic failures. The results of the present SR may provide us with a useful basis for the preparation of management guidelines for the use of new generation therapies in moderate to severe atopic dermatitis.
Keyphrases
- atopic dermatitis
- small molecule
- end stage renal disease
- ejection fraction
- early onset
- chronic kidney disease
- rheumatoid arthritis
- newly diagnosed
- high intensity
- prognostic factors
- peritoneal dialysis
- drug induced
- clinical practice
- patient reported outcomes
- combination therapy
- mass spectrometry
- liquid chromatography
- solid phase extraction